Table 2.
Clinical characterisation and MRI follow-up of NMO patients with longitudinally extensive transverse myelitis (LETM) (n = 23)
|
Clinical manifestations |
F/M |
|
Anti-AQP4 antibodies positive |
F/M |
|
Anti-AQP4 antibodies negative |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of patients = 17 |
|
Number of patients = 6 |
||||||||||||
|
Duration of disease |
EDSS Score |
|
Duration of disease |
EDSS Score |
||||||||||
| 2-4 y | 5-10 y | 2-4 | 5-7 | 8-9 | 2-4 y | 5-10 y | 2-4 | 5-7 | 8-9 | |||||
|
MRI of the spinal cord | ||||||||||||||
| Single LETM |
14/3 |
17 |
10 |
7 |
5 |
5 |
7 |
3/3 |
6 |
3 |
3 |
1 |
4 |
1 |
| Brainstem involvement |
7/0 |
7 |
5 |
2 |
0 |
1 |
6 |
1/0 |
1 |
0 |
1 |
0 |
0 |
1 |
| Relapsing LETM |
4/0 |
4 |
3 |
1 |
0 |
1 |
3 |
1/0 |
1 |
1 |
0 |
0 |
1 |
0 |
| Multiple shorter TM |
5/1 |
6 |
4 |
2 |
0 |
1 |
5 |
1/2 |
3 |
2 |
1 |
0 |
2 |
1 |
| Normal SC |
2/1 |
3 |
3 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Focal atrophy of SC |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3/2 |
5 |
5 |
0 |
0 |
5 |
0 |
| General atrophy of SC | 4/1 | 5 | 4 | 1 | 0 | 0 | 5 | 1/1 | 2 | 1 | 1 | 0 | 0 | 2 |
F/M = Female/male, EDSS = Expanded Disability Status Scale, LETM = longitudinally extensive transverse myelitis, SC = Spinal cord, TM = Transverse myelitis.